Clinical Research Directory
Browse clinical research sites, groups, and studies.
Neoadjuvant Nivolumab with CCR2/5-inhibitor or Anti-IL-8) for Non-small Cell Lung Cancer (NSCLC) or Hepatocellular Carcinoma (HCC)
Sponsor: Icahn School of Medicine at Mount Sinai
Summary
The purpose of this research study is to study the effect of giving nivolumab with CCR2/5-inhibitor or anti-IL-8 before surgery, and after surgery, with the goal of determining if this medicine results in: 1. A significant immune response against their tumor (which the study team will see in the tumor that is taken out at the time of surgery) 2. Improvement in long term survival rates
Official title: Tisch Cancer Institute - BMS Study # CA027-005: Neoadjuvant Nivolumab + BMS-813160 (CCR2/5-inhibitor) or BMS-986253 (anti-IL-8) for NSCLC or HCC
Key Details
Gender
All
Age Range
18 Years - 99 Years
Study Type
INTERVENTIONAL
Enrollment
48
Start Date
2020-03-05
Completion Date
2025-12-31
Last Updated
2025-01-17
Healthy Volunteers
No
Interventions
Nivolumab
q4w, dosed twice before surgery and three times following recovery from surgery by injection
BMS-813160
300mg oral twice a day for 28 days
BMS-986253
2400mg once by injection
Locations (1)
Icahn School of Medicine at Mount Sinai
New York, New York, United States